- A new vaccine designed to protect against both Lassa fever and rabies has shown encouraging trial results, offering a potential solution to two deadly diseases prevalent in parts of Western and Sub-Saharan Africa.
- Lassa fever, a viral hemorrhagic disease transmitted by rodents, is a significant public health threat, causing an estimated 300,000 infections and 5,000 deaths annually, with no vaccine currently available and particularly dangerous during pregnancy.
- Regions affected by Lassa fever also face a high burden of rabies, which causes tens of thousands of deaths each year and is almost always fatal once symptoms develop, highlighting the need for a combined protective measure.
- A study published in Nature Medicine involving 54 healthy US adults demonstrated that the dual vaccine was safe, with no serious reactions reported, and successfully induced immune responses against both the Lassa and rabies viruses.
- Beyond its dual protection, the vaccine can be freeze-dried for storage, which would significantly aid distribution in areas where maintaining a cold chain for medical supplies is challenging, and could help combat the expanding reach of Lassa fever due to climate change.
IN FULL
